Affix Labs Group B.V., a Dutch green chemtech startup, announced a €1 million funding round led by VP Capital and Oost NL to support the European expansion of its sustainable insect repellent technology.
The company is developing a surface insect repellent designed to replace traditional neurotoxic active ingredients, which have contributed to rising insect resistance. Its approach utilizes a water-based, controlled-release system that aims to provide a safer and longer-lasting alternative.
At the core of Affix Labs’ innovation is a patented formulation technology that enables oily, water-insoluble active ingredients to be dissolved into water-based systems. This allows for a controlled-release mechanism that extends effectiveness for up to 12 weeks. Its flagship product, Repeltec, has been dermatologically tested and does not contain neurotoxic compounds.
The funding comes at a time of tightening regulatory scrutiny across Europe. New restrictions on chemical pesticides, including Germany’s 2025 ban on self-service sales of certain neurotoxic insecticides, are reshaping the market landscape. Affix Labs has already secured active substance authorizations for Repeltec in Germany, France, Austria, and Norway.
With the new capital, the company plans to expand distribution across Germany, Austria, France, and Norway, while entering additional markets including the United Kingdom and Poland. In parallel, Affix Labs is launching a white-label B2B offering under the “Powered by Affix Labs” model, enabling FMCG companies, hospitality providers, and pest control manufacturers to integrate its technology into their own product lines.
Founded in the Netherlands, Affix Labs is focused on reducing global reliance on traditional pesticides through its proprietary solubility and controlled-release technologies.
